A study suggests that a reduced dose of enfortumab vedotin may lower toxicity in older patients with urothelial carcinoma, ...
Bladder and Urothelial Cancer Trials to Watch at ESMO 2026 / bladder cancer, cancer, cancer care, Cancer research, cancer ...
Astellas Announced Presentation of 21 Abstracts at ESMO 2026 Including Prostate, Urothelial, GEJ, Lung and Pancreatic cancers ...
American Society for Radiation Oncology (ASTRO) published its first clinical practice guideline on radiation therapy for ...
Enfortumab vedotin-pembrolizumab shows durability advantage over chemotherapy at three-year follow-up in bladder cancer trial ...
A new review in Medical Oncology maps how the tumor microenvironment and gut microbiome drive resistance to immune checkpoint ...
Researchers built a four-gene signature based on propionate metabolism that stratifies colorectal cancer patients by survival ...
In Part 1, I wrote about how cancers of the urinary tract present with the sign of "painless, yet intermittent" hematuria, ...
Zacks Investment Research on MSN
SMMT Inks Deal With AZN-Daiichi to Study Ivonescimab + Datroway Combos
Summit Therapeutics SMMT is expanding the development of its sole investigational drug, ivonescimab, through a new clinical ...
Summit Therapeutics Inc. ( NASDAQ: SMMT) today announced the successful closing of AstraZeneca’s (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued ...
Daiichi Sankyo & AstraZeneca’s Datroway approved in China to treat unresectable or metastatic TNBC who are not candidates for PD-1/PD-L1 inhibitor therapy: Tokyo Friday, October ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results